Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Developing an HCV Vaccine Faces Significant Challenges
Key clinical point: Significant barriers continue to prevent the development of a prophylactic HCV vaccine.
Major finding: HCV has 7 known genotypes and more than 80 subtypes, a genetic diversity exceeding that of HIV-1.
Study details: A literature review of the HCV vaccine development field.
Disclosures: Dr. Bailey and his colleagues reported that they had no conflicts.
Citation:
Bailey JR et al. Gastroenterology 2019;156(2):418-30.